ANNUAL REPORT

anD FINANCIAL

STATEMENTS

for the year ended 31 March 2016

Strong patient growth across all the operating platforms

Continued investments in patient experience and clinical qualities initiatives

Successful completion of Mediclinic and Al Noor Combination and acquisition of 29.9% stake in Spire Healthcare Group

Solid financial performance with stable margins and good cash generation

Revenue growth of 7% with stable margins at 20.3% driving strong underlying earnings growth

Underlying basic earnings per share increased by 3% to 36.7 pence

Proposed final dividend per ordinary share of 5.24 pence

Home_5

CHAIRMAN’S STATEMENT

The period under review was a pivotal one for Mediclinic as we made significant progress in expanding our geographical footprint. I am pleased to report that during this eventful year, we also maintained our 30-year track record of consistent growth.

Edwin Hertzog

Non-executive Chairman